NextPlat (NASDAQ:NXPL) reported $2.87 million in sales this quarter. This is a 46.78 percent increase over sales of $1.96 million the same period last year.
AnaptysBio Announces British Journal Of Dermatology Publication Of Imsidolimab Previously Reported Phase 2 GALLOP Data In Generalized Pustular Psoriasis
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4
Flare control sustained on monthly subcutaneous doses through Week 16
Imsidolimab was generally
